Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation.

Abstract

Percutaneous coronary intervention is evolving rapidly. Among the developments in various aspects, dual antiplatelet therapy (DAPT) has played a pivotal role to reduce thrombotic events after stent implantation. After the introduction of the drug-eluting stent, prolonged DAPT has been recommended due to concerns regarding late and very late stent thrombosis. However, there are controversies regarding the benefit of long-term DAPT. In addition, prolonged DAPT accompanies increased bleeding risk as well as additional cost. To balance the benefit and risk, optimizing DAPT duration is crucial. In this article, clinical guidelines and studies regarding optimal duration of DAPT are discussed.